Benzamides and nicotinamides as Syk modulators

Patent metadata

Field	Value
Publication number	US-9902688-B2
Application number	US-201615151413-A
Country	US
Kind code	B2
Filing date	May 10, 2016
Priority date	Nov 1, 2010
Publication date	Feb 27, 2018
Grant date	Feb 27, 2018

Abstract

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

First claim

What is claimed is:

1. A compound selected from the group consisting of

2. A composition of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.

3. A method for treating a condition or disease selected from the group consisting of a hematological malignancy, rheumatoid arthritis, systemic lupus erythematosus, asthma, and Type 1 diabetes in a subject comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1 .

4. The method of claim 3 , wherein said condition or disease is selected from the group consisting of asthma, systemic lupus erythematosus, and Type I diabetes.

5. The method of claim 3 , wherein said disease is rheumatoid arthritis.

6. The method of claim 3 , wherein said hematological malignancy is selected from the group consisting of acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma.

7. A kit comprising a composition of claim 2 , packaging and instructions for use.

8. The compound of claim 1 , having the formula

9. The compound of claim 1 , having the formula

10. The compound of claim 1 , having the formula

11. The compound of claim 1 , having the formula

12. The compound of claim 1 , having the formula

Assignees

• Portola Pharm Inc

Inventors

• Jia Zhaozhong J
• Song Yonghong
• Xu Qing
• Kane Brian
• Bauer Shawn M
• Pandey Anjali

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title